Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 12/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20290829 | 0.89 | NPC1 (0.47) | METMEN1KMT2AGAASGMS2 | |
| SCHEMBL20291308 | 0.85 | MET (0.53) | METMEN1KMT2AGAASGMS2 | |
| SCHEMBL20290495 | 0.83 | MELK (0.58) | METMEN1KMT2AKDM4EMAPT | |
| SCHEMBL20291307 | 0.78 | LRRK2 (0.45) | METMEN1KMT2AKDM4EMAPT | |
| SCHEMBL16624239 | 0.74 | MAOB (0.61) | MEN1KMT2AMAPTSGMS2 | |
| SCHEMBL1318328 | 0.70 | FFAR4 (0.54) | KDM4EMAPTALDH1A1LMNAGAA | |
| SCHEMBL1316057 | 0.69 | MCL1 (0.56) | MEN1KMT2AKDM4EMAPTALDH1A1 | |
| SCHEMBL20290848 | 0.69 | MELK (0.51) | METMEN1KMT2AGAASGMS2 | |
| SCHEMBL20291125 | 0.69 | MELK (0.73) | METGAASGMS2 | |
| SCHEMBL4481551 | 0.69 | MEN1 (0.67) | MEN1KMT2AKDM4EMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170912-A1 | SALICYLATE INHIBITORS OF MELK AND METHODS OF USE | MELK, HIPK3, MINK1 | MET 615/4885MEN1 1213/4885KMT2A 878/4885 |
| US-10875844-B2 | Salicylate inhibitors of MELK and methods of use | MELK, HIPK3, MINK1 | MET 615/4885MEN1 1213/4885KMT2A 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.